WO2015127848A1 - Substituted phosphoramidate derivative, preparation method therefor, and uses thereof - Google Patents

Abstract

The present invention relates to a substituted phosphoramidate derivative represented by general formula (I), a preparation method therefor, and uses thereof. Definitions of substituent groups in general formula (I) are the same as definitions in the specification.

Description

Substituted phosphoramidate derivative, preparation method thereof and application thereof Technical field

The present invention relates to a substituted phosphoramidate derivative, a process for the preparation thereof and use thereof, and in particular, the present invention relates to a substituted phosphoramidate derivative of the formula (I), which is stereoscopically different Constructs or pharmaceutically acceptable salts, methods for their preparation, and pharmaceutical compositions containing the same, and use in the manufacture of a medicament for the treatment of viral infectious diseases.

Background technique

Hepatitis B is one of the world's diseases, it is caused by hepatitis B virus. A third of the world's population is infected with hepatitis B virus to some extent, including 350 million chronic carriers. In some Asian and African countries, hepatitis B has become a pandemic, especially in China. Hepatitis B virus can cause acute and chronic infections. Acute infections are usually accompanied by inflammation of the liver, vomiting, jaundice, and very few deaths. Chronic infections may induce cirrhosis and liver cancer. Although hepatitis B virus infection can be prevented by vaccines at present, there is no effective method for treating chronic hepatitis B disease.

Hepatitis B virus is a hemorrhagic DNA (DNA) virus with a circular partially double-stranded DNA genome. The shorter one chain has 1700 to 2800 nucleotides, the longer one chain has 3020 to 3320 nucleotides, and this long chain encodes the viral DNA polymerase. The genome of the hepatitis B virus encodes four known genes - C, X, P and S. Gene C encodes a nuclear protein (HBcAg), gene S encodes a surface antigen (HBsAg), and gene P encodes a DNA polymerase. The function of the protein encoded by gene X is unclear, but it is thought to be related to the occurrence of liver cancer because it activates A gene that induces cell proliferation and inactivates growth regulators.

The life cycle of hepatitis B virus is complex, enters cells through unknown receptors and endocytosis, and its genome is transferred to the nucleus by the host protein chaperones. In the nucleus, hepatitis B virus converts part of the double-stranded DNA into intact double-stranded DNA by the DNA polymerase of the host cell, and changes the morphology to a circular DNA (cccDNA) that is bound by a covalent bond. cccDNA was used as a template to transcribe four viral mRNAs. These four transcripts are used as templates to be transported into the cytoplasm and translated into viral membrane proteins, nuclear proteins and DNA polymerases. The longest mRNA (3.5 kb, longer than the viral genome) replicates as a template a new genomic copy, a transcriptional nucleocapsid protein and a viral DNA polymerase. At the same time, this 3.5 kb long RNA will be reverse transcribed from the antisense strand of hepatitis B virus DNA, followed by completion of the viral sense strand. Double-stranded DNA will be exported as a new sub-virus or returned to the nucleus to form a new cccDNA.

Hepatitis B virus RNA and DNA synthesis depends on hepatitis B virus DNA polymerase, hepatitis B virus DNA polymerase Replication of the virus is a must. The polymerase has four domains: a terminal protein important for the initiation of hepatitis B virus replication and assembly of the nucleocapsid, a spacer protein, a reverse transcriptase, and an RNaseH domain for degrading the pre-genomic RNA template. Despite this, the lack of proofreading results in a high mutation rate of hepatitis B virus DNA polymerase.

The use of DNA polymerase inhibitors as anti-HBV drugs has become an attractive option. A particular viral polymerase inhibitor belongs to the family of nucleoside analogs. Treatment for patients with chronic hepatitis B has been improved by oral administration of anti-HBV nucleoside analog drugs. In serum, nucleoside analogs can rapidly reduce HBV DNA to unpredictable levels, and the mechanism of action is clear: nucleoside analogs competitively inhibit the activity of viral DNA polymerase. At the same time, nucleoside analogs showed good tolerance and fewer adverse reactions than interferon IFN-α. To date, five nucleoside analogues, hepatitis B virus DNA polymerase inhibitors, have been marketed as drugs for the treatment of chronic hepatitis B in the United States and Europe, including: lamivudine, and fosfovir dipivoxil. Entecavir, telbivudine and tenofovir disoproxil fumarate, as well as several other drugs at the stage of research. At the same time, long-term antiviral therapy may cause viral resistance and selectivity due to virus residues in the liver and mutations caused by viral polymerases, including mutations in the viral polymerase amino acid. This puts requirements on the development of new antiviral drugs.

Tenofovir, chemical name [(1R)-2-(6-aminofluoren-9-yl)-1-methyl-ethoxy]methyl phosphate (PMPA), is a nucleoside An acid reverse transcriptase inhibitor has anti-HBV and HIV; however, it has disadvantages such as having a phosphoric acid group, having a large polarity, a poor biofilm penetrating ability, and poor bioavailability in a living body. To overcome this disadvantage, a phosphonate or phosphonamide prodrug form can be made. Viread (Tinofovir dipivoxil fumarate), a drug developed by Gilead in 2002, is a prodrug of PMPA, and the prodrug form of the phosphonate is greatly improved in bioavailability. Viread plays an important role in the treatment of HIV and HBV. The transformation of the form of tenofovir prodrugs has become a hot topic of research.

Ezetimibe is a new cholesterol absorption inhibitor developed by Schering-Plough. It was approved by the FDA in October 2002 under the trade name Zetia. The chemical name is (1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)- 2-azetidinone, a selective cholesterol absorption inhibitor that blocks the exogenous absorption pathway of cholesterol. It inhibits the absorption of cholesterol in the diet and bile transport to the intestine by lowering the intestinal membrane protein NPC1L1 in the small intestine brush border membrane, and lowers the cholesterol content in serum and liver. Ulrike Protzer et al. (Antiviral Research, 2013 (97), 195-197.) reported its activity in inhibiting HBV infection in 2013. Professor Li Wenhui et al. (eLife, 2012; 1:e00049.) reported in 2012 a hepatitis B virus receptor-Sodium taurocholate cotransporting polypeptide (NTCP, sodium ion-taurocholic acid-co-transporter). James E.Polli et al. (Mol. Pharmaceutics, 2013 (10), 1008-1019.) reported in 2013 that ezetimibe is capable of inhibiting NTCP protein. The above studies show that ezetimibe can exert anti-HBV.

European Patent No. EP206459 describes a structure comprising tenofovir for 9- (methoxy phosphate alkyl) adenine derivatives, and their use for antiviral drugs, in which R ¹ selected from hydrogen, methyl, hydroxymethyl, R ^{2 is} selected from substituted or unsubstituted ethylene, methylene, propylene, and the like. The detailed description in this patent is not considered to be part of the present invention, and its structural formula is as follows:

EP 481214 describes a novel oral phosphate nucleoside analog prodrug comprising adefovir dipivoxil, and its antiviral medical use, in particular anti-RNA, DNA virus, can also be used for the treatment of tumors, etc., wherein B is selected from嘌呤, cytosine, uracil, thymine, ornithril, etc., R ^{3 is} selected from substituted or unsubstituted C ₁ -C ₂₀ alkyl, R ¹ , R ^{2 are} independently selected from substituted or unsubstituted amino, OR ⁴ , R ⁴ is selected from _{CH 2 C (O) N (} R 5) 2, CH 2 C (O) OR 5, CH2OC (O) R 5, CH (R 5) OC (O) R 5, CH 2 C ( R ⁵ ) ₂ CH ₂ OH or CH ₂ OR ⁵ , R ^{5 is} selected from C ₄ -C ₂₀ alkyl, aryl or aryl-alkyl groups which are unsubstituted or substituted by hydroxy, oxo, nitro, halogen, R1 R2 can be looped. The specific description in this patent is not considered to be part of the present invention and its structure is as follows:

WO0208241 describes compositions comprising a derivative of adenine for disoproxil structure, in which R ¹ selected from hydrogen, methyl. The detailed description in this patent is not considered to be part of the present invention, and its structural formula is as follows:

WO02057288 describes substituted phosphoramidate derivatives and their use in antiviral drugs, wherein Q is selected from purine or pyrimidine, R ⁴ and R ^{5 are} independently selected from hydrogen, alkyl, aryl, etc., R ¹ , R ² , R ³ , R ⁷ and R ^{8 are} independently selected from a hydroxyl group, a halogen, a hydrogen, an amino group, an alkyl group, an alkoxy group, an alkylamino group and the like. The detailed description in this patent is not considered to be part of the present invention, and its structural formula is as follows:

CN200410024276.X describes 9-((phosphate)methoxyalkyl)adenine derivatives and their use in antiviral drugs, wherein R ¹ and R ^{2 are} independently selected from hydrogen or substituted biphenylmethyl . The detailed description in this patent is not considered to be part of the present invention, and its structural formula is as follows:

CN200710041280.0 describes substituted amino phosphate derivatives and their use for antiviral, wherein R ¹ is selected from hydrogen, halo, amino, cyclopropylamino, methoxy, ethoxy, R ² It is selected from hydrogen or amino, R ^{5 is} selected from methyl or hydrogen, and R ³ and R ^{4 are} independently selected from (substituted aminocarbonyloxy)alkyl. The detailed description in this patent is not considered to be part of the present invention, and its structural formula is as follows;

CN200410088840.4 describes substituted phosphoramidate derivatives and their use in antiviral drugs, wherein R is hydrogen or methyl, R ^{2 is} selected from hydrogen or camphoryl, and R ^{1 is} selected from 3-8 carbons. A cycloalkyl group, a 3-8 carbon unsaturated chain hydrocarbon group, a 3-8 carbon unsaturated cycloalkyl group or a 6-10 carbon aromatic hydrocarbon. The specific description in this patent is not considered to be part of the present invention, and its structural formula is as follows

WO2011069322 describes substituted amino phosphate derivatives and their use for the treatment and prevention of diseases associated with viral infections medical uses, in which R ¹ is selected from hydrogen or methyl, R ² is selected from -R ³ or -OR ^3, R ^{3 is} selected from the group consisting of C _1-8 alkyl groups and C _3-8 cycloalkyl groups. The detailed description in this patent is not considered to be part of the present invention, and its structural formula is as follows:

The invention designs a compound represented by the general formula (I) on the basis of tenofovir disoproxil to provide a novel structure, better medicine, safer, less toxic and side effects, good solubility or high bioavailability. Substituted phosphoramidate derivatives, stereoisomers or pharmaceutically acceptable salts thereof, for use in the treatment of viral infectious diseases, including infectious diseases caused by hepatitis B virus and HIV virus.

Summary of the invention

The present invention provides a substituted phosphoramidate derivative represented by the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein:

A is selected from phenyl or naphthyl, and the phenyl or naphthyl group is further optionally 0 to 5 selected from the group consisting of H, F, Cl, Br, I, amino, hydroxy, carboxy, C _1-4 alkyl or Substituted by a substituent of a C _1-4 alkoxy group;

B is

E is selected from -CH(CH ₂ F)CH ₂ -, -CH ₂ CH(CH ₃ )OCH ₂ - or -CH ₂ CH ₂ OCH ₂ -;

R ^{1 is} selected from H or C _1-4 alkyl;

R ² is a side chain of a natural or pharmaceutically acceptable amino acid, and if the side chain contains a carboxyl group, the carboxyl group may be optionally esterified with an alkyl group or an aryl group;

R ³ is

R ^{4 is} selected from H, formyl, C _1-4 alkyl, -(CH ₂ ) _n -C _3-6 carbocyclic, -(C=O)-C _1-4 alkyl or -(C=O) -C _3-6 carbon ring;

n is selected from 0, 1, or 2.

A preferred embodiment of the invention, a substituted phosphoramidate derivative of the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein A is selected from phenyl or naphthyl, preferably phenyl; The phenyl or naphthyl group is optionally further substituted with from 0 to 5 substituents selected from H, F, Cl, Br, I, amino, hydroxy, carboxy, methyl, ethyl, methoxy or ethoxy. Substituted, it is further preferably substituted with 0 to 5 substituents selected from H, F, Cl, Br, amino or methoxy.

An alternative of the present invention, a substituted phosphoramidate derivative of the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein R ² is a natural or pharmaceutically acceptable amino acid a side chain in which the amino acids are preferably glycine, alanine, leucine, isoleucine, tyrosine, valine, phenylalanine, methionine, tryptophan, serine, glutamine, Threonine, cysteine, histidine, asparagine, tyrosine, aspartic acid, glutamic acid, naphthyl acid or arginine, further preferably glycine, alanine, leucine, Phenylalanine, asparagine or arginine, more preferably glycine, alanine or phenylalanine.

An alternative of the present invention, a substituted phosphoramidate derivative represented by the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein R ^{4 is} selected from the group consisting of H, formyl, C _{1- 4-} alkyl, -(CH ₂ ) _n -C ₅ carbocyclic, -(CH ₂ ) _n -C ₆ carbocyclic, -(C=O)-C _1-4 alkyl, -(C=O)-C _{a 5-} carbon ring or a -(C=O)-C ₆ carbocyclic ring, preferably H, methyl, phenyl, benzyl, formyl, acetyl or benzoyl, further preferably H, benzyl, formyl, acetyl Or benzoyl.

A preferred embodiment of the present invention, a substituted phosphoramidate derivative represented by the formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the substituted phosphoramidate derivative is selected from the group consisting of a compound shown in (II), wherein:

E is selected from -CH ₂ CH(CH ₃ )OCH ₂ - or -CH ₂ CH ₂ OCH ₂ -, preferably -CH ₂ CH(CH ₃ )OCH ₂ -;

R ^{2 is} selected from the side chain of glycine, alanine, leucine, phenylalanine, asparagine or arginine, preferably a side chain of glycine, alanine or phenylalanine;

R ^{4 is} selected from H, methyl, phenyl, benzyl, formyl, acetyl or benzoyl, preferably H, benzyl, formyl, acetyl or benzoyl.

A preferred embodiment of the present invention, a substituted phosphoramidate derivative represented by the formula (II), a stereoisomer thereof or a pharmaceutically acceptable salt, wherein

E is selected from -CH ₂ CH(CH ₃ )OCH ₂ -;

R ^{2 is} selected from the side chain of glycine, alanine or phenylalanine;

R ^{4 is} selected from H, benzyl, formyl, acetyl or benzoyl.

A preferred embodiment of the present invention, a substituted phosphoramidate derivative represented by the formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the substituted phosphoramidate derivative is selected from the group consisting of a compound shown by (III), wherein:

Preferred Embodiments of the Invention, a substituted phosphoramidate derivative of the formula (III), a stereoisomer or a pharmaceutically acceptable salt thereof, wherein R ^{2 is} selected from the group consisting of glycine, alanine, and leucine a side chain of phenylalanine, asparagine or arginine, preferably a side chain of glycine, alanine or phenylalanine;

R ^{4 is} selected from H, methyl, phenyl, benzyl, formyl, acetyl or benzoyl, preferably H, benzyl, formyl, acetyl or benzoyl, further preferably H.

The substituted phosphoramidate derivative according to claim 1, which is a stereoisomer or a pharmaceutically acceptable salt, wherein the substituted phosphoramidate derivative is:

The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a substituted phosphoramidate derivative of the present invention, and a stereoisomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable pharmaceutical composition An acceptable carrier or excipient.

Further, the present invention provides the use of the substituted phosphoramidate derivative of the present invention, a stereoisomer thereof or a pharmaceutically acceptable salt thereof for the preparation of a medicament for treating a viral infectious disease.

A preferred embodiment of the present invention, wherein the viral infectious disease comprises hepatitis B virus, hepatitis C virus, and Infectious diseases caused by HIV.

Further, the present invention provides a method of treating a viral infectious disease, wherein the method comprises administering a substituted phosphoramidate derivative of the present invention, a stereoisomer thereof or a pharmaceutically acceptable thereof Salt or a pharmaceutical composition of the invention.

A preferred embodiment of the invention, wherein the viral infectious disease comprises an infectious disease caused by hepatitis B virus, hepatitis C virus and HIV virus.

Terms used in the specification and claims have the following meanings unless stated to the contrary.

The present invention relates to the substitution of a plurality of substituents, which may be the same or different.

The present invention relates to the inclusion of a plurality of heteroatoms, each of which may be the same or different.

The elements carbon, hydrogen, oxygen, sulfur, nitrogen or halogen involved in the groups and compounds of the present invention include their isotopic conditions, and the elements, carbon, hydrogen and oxygen involved in the groups and compounds of the present invention. Sulfur or nitrogen is optionally further replaced by one or more of their corresponding isotopes, wherein the carbon isotopes include ¹² C, ¹³ C, and ¹⁴ C, and the hydrogen isotopes include helium (H), helium (D, also known as heavy hydrogen ), 氚 (T, also known as super heavy hydrogen), oxygen isotopes include ¹⁶ O, ¹⁷ O and ¹⁸ O, sulfur isotopes include ³² S, ³³ S, ³⁴ S and ³⁶ S, nitrogen isotopes including ¹⁴ N and ¹⁵ N The fluorine isotope ¹⁹ F, the chlorine isotope includes ³⁵ Cl and ³⁷ Cl, and the bromine isotopes include ⁷⁹ Br and ⁸¹ Br.

The term "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight chain and branched chain groups of 1 to 20 carbon atoms. Preference is given to alkyl groups having 1 to 10 carbon atoms, non-limiting examples including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, positive a mercapto group, and various branched isomers thereof; more preferred are lower alkyl groups having 1 to 4 carbon atoms, and non-limiting examples include methyl, ethyl, propyl, isopropyl, and Butyl, isobutyl or tert-butyl. The alkyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably from 1 to 5, independently selected from the group consisting of H, F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl. , alkoxy, alkylthio, alkylamino, fluorenyl, hydroxy, nitro, cyano, amino, alkyl acylamino, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy A cycloalkylalkyl group, a hydroxyalkyl group, a carboxylic acid, a carboxylic acid ester or a heterocycloalkyl group.

"Alkoxy" means an -O-alkyl group wherein alkyl is as defined above. The alkoxy group may be substituted or unsubstituted, and non-limiting examples thereof include methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, pentyloxy or The hexyloxy group preferably has a 1 to 12 member alkoxy group. When substituted, the substituent is preferably from 1 to 5, independently selected from the group consisting of H, F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkyl Amino, mercapto, hydroxy, nitro, cyano, amino, alkyl acylamino, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylindolyl, hydroxyalkyl, A carboxylic acid, a carboxylic acid ester or a heterocycloalkyl fluorenyl group.

"Carbocycle" means a saturated or unsaturated aromatic ring or a non-aromatic ring, and the aromatic ring or non-aromatic may be 3 to 8 Monocyclic, 4 to 12 membered bicyclic or 10 to 15 membered tricyclic system, the carbocyclic ring may be attached to a bridged or spiro ring, non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl , cyclohexenyl, cycloheptyl, cyclopentene, cyclohexadiene, cycloheptatriene, phenyl, naphthyl, benzocyclopentyl, bicyclo[3.2.1]octyl, bicyclo [ 5.2.0] decyl, tricyclo [5.3.1.1] dodecyl, adamantyl or spiro[3.3] heptyl and the like. The carbocyclic ring may be substituted, and when substituted, the substituent is preferably from 1 to 5, independently selected from the group consisting of H, F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl, alkoxy, Alkyl, alkylamino, sulfhydryl, hydroxy, nitro, cyano, amino, alkyl acylamino, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkyl fluorenyl A hydroxyalkyl group, a carboxylic acid, a carboxylic acid ester or a heterocycloalkyl fluorenyl group.

"Heterocycle" means a substituted or unsubstituted saturated or unsaturated aromatic or non-aromatic ring, and the aromatic and non-aromatic rings may be a 3 to 8 membered monocyclic ring, a 4 to 12 membered bicyclic ring or a 10 to 15 membered member. A tricyclic system consisting of at least one hetero atom selected from N, O or S, preferably a 3 to 10 membered heterocyclic ring, and optionally substituted N, S in the heterocyclic ring can be oxidized to various oxidation states. The heterocyclic ring can be attached to a hetero atom or a carbon atom. The heterocyclic ring may be attached to a bridged or spiro ring, and non-limiting examples include, ethylene oxide, aziridine, oxetanyl, azetidinyl, 1,3-dioxolane, 1,4-dioxolane, 1,3-dioxane, azepanyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl , pyridazinyl, imidazolyl, piperidinyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithiane, dihydrofuran, dihydropyran, dithiapentane, tetrahydrofuran, Tetrahydropyrrolyl, tetrahydroimidazole, tetrahydrothiazole, tetrahydropyran, benzimidazole, benzopyridine, pyrrolopyridine, benzodihydrofuran, azabicyclo[3.2.1]octyl, nitrogen Heterobicyclo[5.2.0]nonane, oxatricyclo[5.3.1.1]dodecyl, azaadamantyl, oxaspiro[3.3]heptyl, etc.; when substituted, substituent Preferably from 1 to 5, the substituents are independently selected from the group consisting of H, F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, fluorenyl, hydroxy , nitro, cyano, amino, alkyl acylamino, heterocycloalkyl, ring Alkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylfluorenyl, hydroxyalkyl, carboxylic acid, carboxylic acid ester, heterocycloalkyl fluorenyl, -(CH ₂ ) _n S (=O) _p R ⁶ , -(CH ₂ ) _n -alkenyl-R ⁶ or -(CH ₂ ) _n -alkynyl-R ⁶ .

"Amino" means -NH _2, may be substituted or unsubstituted. When substituted, the substituent is preferably 1 to 3, independently selected from alkyl, alkenyl, alkynyl, alkoxy, Thio, hydroxy, amino, alkylamino, alkyl acylamino, heterocycloalkyl, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, hydroxyalkyl, carboxylic acid or Carboxylic acid ester.

"Aryl" means a substituted or unsubstituted 6 to 14 membered all carbon monocyclic or fused polycyclic group having a polycyclic group of a conjugated π-electron system, preferably a 6 to 10 membered aromatic ring, Non-limiting examples include phenyl or naphthyl; the aryl group may be fused to a heteroaryl, heterocyclyl or cycloalkyl group, and the moiety attached to the parent structure is an aryl group, which is non-limiting Examples include benzofuran, benzocyclopentyl or benzothiazole and the like. When substituted, the substituent is preferably from 1 to 5, and the substituent is independently selected from the group consisting of H, F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, fluorenyl, hydroxy, nitro, cyano, amino, alkyl acylamino, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylindolyl, hydroxyalkane a carboxylic acid, a carboxylic acid ester or a heterocycloalkyl fluorenyl group.

"Heteroaryl" means a substituted or unsubstituted 5 to 15 membered aromatic ring and contains 1 to 3 heteroatoms selected from N, O or S heteroatoms, preferably 5 to 10 members, and non-limiting heteroaryl groups. Examples include pyridyl, furyl, thienyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzofuran, benzimidazole, benzopyridine or pyrrolopyridine, and the like. When substituted, the substituent is preferably from 1 to 5, and the substituent is independently selected from the group consisting of H, F, Cl, Br, I, =O, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, Alkylamino, fluorenyl, hydroxy, nitro, cyano, amino, alkyl acylamino, cycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylindolyl, hydroxyalkane a carboxylic acid, a carboxylic acid ester or a heterocycloalkyl fluorenyl group.

"Natural or pharmaceutically acceptable amino acids": The basic skeleton of a protein molecule is an amino acid sequence, and there are 20 basic amino acids constituting a protein. These 20 basic amino acids are the basis for biological late modification of proteins, and in addition, based on these basic amino acids. The organism also synthesizes amino acid types derived from hydroxyproline, hydroxylysine, etc. These biosynthesized amino acids are collectively referred to as "natural amino acids"; artificially synthesized are "unnatural amino acids". "Pharmaceutically acceptable amino acid" refers to a pharmaceutically acceptable natural or unnatural amino acid.

The "=O" of the present invention is generally used in the art and refers to an oxygen atom bonded by a double bond, such as a double bond oxygen atom to a carbon atom in a carbonyl group.

"Pharmaceutically acceptable salt" means a pharmaceutically acceptable salt of a non-toxic acid or base, including salts of inorganic acids and bases, organic acids and bases.

"Crystal" refers to a combination of an active pharmaceutical ingredient (API) and a cocrystal former (CCF) under the action of hydrogen bonds or other non-covalent bonds, of which API and CCF The pure state is solid at room temperature and there is a fixed stoichiometric ratio between the components. Eutectic is a multi-component crystal that contains both a binary eutectic formed between two neutral solids and a multi-component eutectic formed by a neutral solid with a salt or solvate. The "eutectic former" includes, but is not limited to, various pharmaceutically acceptable acid, base, nonionic compounds,

"Stereoisomer" refers to isomers resulting from the spatial arrangement of atoms in a molecule, including cis and trans isomers, enantiomers and conformational isomers.

"Pharmaceutical composition" means one or more of the compounds described herein or a physiologically/pharmaceutically acceptable salt or mixture of prodrugs thereof with other chemical components, such as physiological/pharmaceutically acceptable carriers and excipient. medicine The purpose of the composition is to facilitate the administration of the compound to the organism.

"Prodrug" means a compound of the invention which can be converted to biological activity under physiological conditions or by solvolysis. Prodrugs of the invention are prepared by modifying functional groups in the compound which can be removed by conventional procedures or in vivo to provide the parent compound. A prodrug includes a compound formed by attaching a hydroxyl group, an amino group or a thiol group to any group in the compound of the present invention. When a prodrug of the compound of the present invention is administered to a mammalian individual, the prodrug is cleaved to form a free hydroxyl group, respectively. , free amino or free sulfhydryl. Examples of prodrugs include, but are not limited to, compounds formed by the hydroxyl or amino functional groups of the compounds of the invention with formic acid, acetic acid or benzoic acid.

"Optional", "optional" or "optionally" means that the event or environment described subsequently may, but need not, occur, including where the event or environment occurs or does not occur. For example, "aryl substituted with an alkyl group" means that an alkyl group may, but need not, be present, and the description includes the case where the aryl group is substituted with an alkyl group and the case where the aryl group is not substituted with an alkyl group.

"Substituted or unsubstituted" refers to a situation in which a group may be substituted or unsubstituted, and if it is not indicated in the present invention that a group may be substituted, it means that the group is unsubstituted.

“As a choice” means that the scheme after “as a choice” is a side-by-side relationship with the scheme before “as a choice” rather than a further selection in the previous scheme.

"Substitution" refers to the case where one or more hydrogen atoms in a group are substituted by another group, and if the group is substituted by a hydrogen atom, the group formed is the same as the group substituted by a hydrogen atom. Where the group is substituted, for example, amino, C _1-4 alkyl, C _1-4 alkoxy, C _3-6 carbocyclic, 3 to 6 membered heterocyclic ring, optionally further from 0 to 4 selected from H, Substituted by a substituent of F, Cl, Br, I, hydroxy, cyano, amino, C _1-4 alkyl or C _1-4 alkoxy, the groups formed include, but are not limited to, methyl, chloromethyl, Trichloromethyl, hydroxymethyl, -CH ₂ OCH ₃ , -CH ₂ SH, -CH ₂ CH ₂ CN, -CH ₂ NH ₂ , -NHOH, -NHCH ₃ , -OCH ₂ Cl, -OCH ₂ OCH ₂ CH ₃ , -OCH ₂ CH ₂ NH ₂ , -OCH ₂ CH ₂ SH, -OCH ₂ CH ₂ OH, 1-hydroxycyclopropyl, 2-hydroxycyclopropyl, 2-aminocyclopropyl, 4-methyl Furanyl, 2-hydroxyphenyl, 4-aminophenyl or phenyl.

Specific synthesis method of the invention

When R ^{4 is} not H: under basic conditions, after compound IA and compound IB are reacted, compound IC is added, and after completion of the reaction, compound I is obtained;

When R ⁴ is H: under basic conditions, after compound IA and compound IB are reacted, compound IC is further added, and after completion of the reaction, compound R is obtained by removing the R ⁵ group by a usual method for removing the protecting group.

Wherein the definitions of R ¹ , R ² , and R ⁴ are consistent with the definitions of Formula I;

R ^{5 is} selected from C _1-4 alkyl, -(CH ₂ ) _n -C _3-6 carbocyclic, -(C=O)-C _1-4 alkyl or -(C=O)-C _3-6 Carbon ring

n is selected from 0, 1, or 2.

detailed description

The technical solutions of the present invention are described in detail below with reference to the accompanying drawings and embodiments, but the scope of protection of the present invention includes but is not limited thereto.

The structure of the compound is determined by nuclear magnetic resonance (NMR) or (and) mass spectrometry (MS). The NMR shift (δ) is given in units of 10 ^-6 (ppm). NMR was measured using a (Bruker Avance III 400 and Bruker Avance 300) NMR instrument and the solvent was deuterated dimethyl sulfoxide (DMSO-d ₆ ), deuterated chloroform (CDCl ₃ ), deuterated methanol (CD ₃ OD). The internal standard is tetramethylsilane (TMS).

The measurement of MS was carried out (Agilent 6120B (ESI) and Agilent 6120B (APCI)).

The HPLC was measured using an Agilent 1260 DAD high pressure liquid chromatograph (Zorbax SB-C18 100 x 4.6 mm).

Thin layer chromatography silica gel plate uses Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plate. The specification of silica gel plate used for thin layer chromatography (TLC) is 0.15mm~0.20mm. The specification for thin layer chromatography separation and purification is 0.4mm. ~0.5mm.

Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as a carrier.

The known starting materials of the present invention may be synthesized by or according to methods known in the art, or may be purchased from Titan Technology, Anheji Chemical, Shanghai Demer, Chengdu Kelon Chemical, Suiyuan Chemical Technology, and Belling Technology. And other companies.

The nitrogen atmosphere means that the reaction flask is connected to a nitrogen balloon having a volume of about 1 L.

The hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon of about 1 L volume.

The hydrogenation reaction is usually evacuated, charged with hydrogen, and operated three times.

Unless otherwise stated in the examples, the reaction was carried out under a nitrogen atmosphere.

Unless otherwise stated in the examples, the solution means an aqueous solution.

There is no particular description in the examples, and the reaction temperature is room temperature.

The room temperature is an optimum reaction temperature of 20 ° C to 30 ° C.

Intermediate 1

6-Amino-9-[(2R)-2-(dichlorophosphorylmethoxy)propyl]indole (Intermediate 1)

9-[(2R)-2-(dichlorophosphorylmethoxy)propyl]purin-6-amine

First step: 6-amino-9-[(2R)-2-(dichlorophosphorylmethoxy)propyl]indole (intermediate 1)

9-[(2R)-2-(dichlorophosphorylmethoxy)propyl]purin-6-amine

[[(1R)-2-(6-Aminofluoren-9-yl)-1-methylethoxy]methyl]phosphoric acid (20 g, 0.07 mmol) was dissolved in acetonitrile (300 mL) The sulfone (50 g, 0.42 mmol) was heated to reflux for 3 hours. The reaction solution was cooled to room temperature and concentrated to give the title compound 6-amino-9-[(2R)-2-(dichlorophosphorylmethoxy)propyl] hydrazide ( Intermediate 1) as a yellow solid (22.7 g. Rate is 100%).

Example 1

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo-nitrogen Heterocyclobutane-3-yl)]propyl ester-(2S)-2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methylethoxy]methylbenzene Oxy]phosphoryl]amino]propionic acid

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo-azetidin-3-yl)]propyl -(2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methylethoxy]methylphenoxy]phosphory]amino]propanoate

First step: (1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)-4 -oxo-azetidin-3-yl)n-propanol (1B)

(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-Benzyloxyphenyl)-4-oxo-azetidin-3-yl)propan-1 -ol

(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo-nitrogen Heterocyclobutane-3-yl)-n-propanol (1A) (20 g, 0.0488 mmol) was dissolved in N,N-dimethylformamide (20 mL). 0.2442 mmol) and cesium carbonate (27 g, 0.0823 mmol) were maintained at room temperature for 3 hours. Water (500 mL) was added to the mixture, and the mixture was evaporated, evaporated, evaporated, evaporated, evaporated The title compound (1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)-4 was obtained. -Oxo-azetidin-3-yl)n-propanol (1B), white solid (24 g, yield 99%).

_{1H NMR (400MHz, CDCl 3)} δ7.43-7.21 (m, 11H), 7.04-6.89 (m, 6H), 5.05 (s, 2H), 4.71 (t, 1H), 4.57 (d, 1H), 3.09 -3.06 (m, 1H), 2.04-1.83 (m, 4H).

Second step: [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)- 4-oxo-azetidin-3-yl))propyl-(2S)-2-(tert-butoxycarbonylamino)propionic acid-(1C)

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-Benzyloxyphenyl)-4-oxo-azetidin-3-yl)]propyl -(2S)-2-(tert-butoxycarboxylamino)propanoate

(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)-4-oxo -azetidin-3-yl)n-propanol (1B) (12 g, 24 mmol) was dissolved in dichloromethane (200 mL) and (2S)-2-(tert-butoxycarbonylamino)propanoic acid ( 4.5 g, 24 mmol), a solution of dicyclohexylcarbodiimide (4.9 g, 24 mmol) in dichloromethane (50 mL) and 4-dimethylaminopyridine (2 g, 24 mmol) (50 mL) solution, reacted overnight. The reaction mixture was filtered over Celite (EtOAc) (EtOAc) (EtOAc) 1 to 1:9) to give the title compound [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxy) Phenyl)-4-oxo-azetidin-3-yl))propyl-(2S)-2-(tert-butoxycarbonylamino)propionic acid (1C), white solid (11 g, 69 %).

_{1H NMR (400MHz, CDCl 3)} δ7.45-7.31 (m, 5H), 7.29-7.19 (m, 6H), 7.04-6.95 (m, 4H), 6.95-6.89 (m, 2H), 5.73 (t, 1H), 5.05 (s, 2H), 4.95 (d, 1H), 4.55 (d, 1H), 4.32 (m, 1H), 3.03 (m, 1H), 2.11-2.00 (m, 2H), 1.98-1.77 (m, 2H), 1.42 (s, 9H), 1.29 (d, 3H).

The third step: [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)- 4-oxo-azetidin-3-yl)]propyl ester-(2S)-2-aminopropionic acid-(1D)

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-Benzyloxyphenyl)-4-oxo-azetidin-3-yl)]propyl -(2S)-2-aminopropanoate

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)-4-oxo -(Azetidin-3-yl))propyl-(2S)-2-(tert-butoxycarbonylamino)propanoic acid (1C) (11 g, 16.4 mmol) dissolved in dichloromethane (50 mL) After cooling to 0 ° C, trifluoroacetic acid (18.7 g, 164 mmol) was added, and the mixture was warmed to room temperature for 1 hour. The reaction solution was cooled to 0 ° C, water (100 mL) and dichloromethane (100 mL) was added, and the solution was adjusted to pH 8 with aqueous ammonia, and the organic layer was washed with saturated brine (100 mL). The title compound [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)-4 was obtained -Oxo-azetidin-3-yl)] propyl ester-(2S)-2-aminopropionic acid (1D), mp.

_{1H NMR (400MHz, CDCl 3)} δ7.45-7.31 (m, 5H), 7.30-7.17 (m, 6H), 7.05-6.95 (m, 4H), 6.95-6.88 (m, 2H), 5.71 (t, 1H), 5.05 (s, 2H), 4.54 (d, 1H), 3.59 (q, 1H), 3.06 (m, 1H), 2.09-2.02 (m, 2H), 1.89-1.79 (m, 2H), 1.29 (d, 3H).

Fourth step: [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)- 4-oxo-azetidin-3-yl)]propyl ester-(2S)-2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methyl) Oxy]methylphenoxy]phosphoryl]amino]propionic acid-(1E)

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-Benzyloxyphenyl)-4-oxo-azetidin-3-yl)]propyl -(2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methylethoxy]methylphenoxy]phosphory]amino]propanoate

6-Amino-9-[(2R)-2-(dichlorophosphorylmethoxy)propyl]indole (Intermediate 1) (15.3 g, 0.0474 mmol) was dissolved in dichloromethane and cooled to -40 Add ~(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxybenzene) dropwise at -30 °C 4-oxo-azetidin-3-yl)]propyl ester-(2S)-2-aminopropionic acid (1D) (9 g, 0.0158 mmol) A solution of triethylamine (12.8 g, 0.126 mmol) in dichloromethane (80 mL) was chromatographed to [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1- (4-Fluorophenyl)-2-(4-benzyloxyphenyl)-4-oxo-azetidin-3-yl)]propyl-(2S)-2-aminopropionic acid A solution of phenol (8.9 g, 0.094 mmol) in dichloromethane (50 mL) was added dropwise, and the mixture was warmed to room temperature for 1 hour. Water (20 mL) was added to the reaction mixture, and the mixture was evaporated. mjjjjjjjjjjjjjjj 19) The title compound [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl) was obtained. 4-oxo-azetidin-3-yl)]propyl ester-(2S)-2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methyl) Ethoxy]methylphenoxy]phosphoryl]amino]propionic acid (1E), pale yellow solid (9 g, yield 62%).

1H NMR (400MHz, CDCl ₃ ) δ 8.30 (d, 1H), 7.94 (d, 1H), 7.46-7.30 (m, 5H), 7.29-7.17 (m, 8H), 7.10 (m, 2H), 7.02 -6.88(m,7H),5.88(s,2H), 5.74-5.63(m,1H),5.06(s,2H),4.52(dd,1H),4.42-4.27(m,1H), 4.20-4.05 (m, 2H), 3.97-3.80 (m, 2H), 3.71-3.55 (m, 2H), 3.02 (td, 1H), 2.08-2.00 (m, 2H), 1.93-1.75 (m, 2H), 1.26 (d, 3H), 1.15 (m, 3H).

MS M/Z (ESI): 915.5 (M + 1).

Ms: 915.5 (M+1).

The fifth step: [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4- Oxo-azetidin-3-yl)]propyl ester-(2S)-2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methylethoxy) ]Methylphenoxy]phosphoryl]amino]propionic acid-(Compound 1)

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo-aze tidin-3-yl)] Propyl-(2S)-2-[[[(1R)-2-(6-aminopurin-9-yl)-1-methylethoxy]methylphenoxy]phos phory]amino]propanoate

[(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-benzyloxyphenyl)-4-oxo -azetidin-3-yl)]propyl ester-(2S)-2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methylethoxy]] Methylphenoxy]phosphoryl]amino]propionic acid (1E) (4g, 4.36mmol) was dissolved in methanol (50mL), acetic acid (5mL), and palladium carbon (0.8g), under hydrogen atmosphere, often The reaction was carried out for 2 days. The reaction solution was filtered through celite, and filtered and washed with dichloromethane. The residue was purified by silica gel column chromatography (mjjjjjjjjj ((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo-azetidin-3-yl)]propyl-(2S)- 2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methylethoxy]methylphenoxy]phosphoryl]amino]propanoic acid (Compound 1), white solid (2 g, yield 55.5%).

_{1H NMR (400MHz, CDCl 3)} δ8.30 (d, 1H), 7.99 (d, 1H), 7.25-7.13 (m, 6H), 7.07 (m, 4H), 6.97 (m, 3H), 6.87 (m , 4H), 6.06 (s, 2H), 5.65 (q, 1H), 4.49 (m, 1H), 4.44 - 4.27 (m, 1H), 4.18-3.99 (m, 2H), 3.90-3.65 (m, 3H) ), 3.65-3.56 (m, 1H), 3.03-2.90 (m, 1H), 1.98 (m, 2H), 1.83-1.69 (m, 2H), 1.22 (m, 3H), 1.15 (m, 3H).

MS M/Z (ESI): 825.6 (M + 1).

Example 2 Resolution of Compound 1

Taking [(1S)-1-(4-fluorophenyl)-3-((2S,3R)-1-(4-fluorophenyl)-2-(4-hydroxyphenyl)-4-oxo- Azetidin-3-yl)]propyl ester-(2S)-2-[[[(1R)-2-(6-aminofluoren-9-yl)-1-methylethoxy]methyl Phenoxy]phosphoryl]amino]propionic acid (Compound 1) (800 mg) was used for resolution.

Preparation conditions: Instrument: Thar 80 preparative SFC; Column: ChiralPak AS-20u, 250 x 50 mm I.D.; Mobile phase: A: CO ₂ , B: methanol; Gradient: B 35%; Flow: 70 mL/min; Back pressure: 100 bar; column temperature: 38 ° C; wavelength: 220 nm; period: 12 min; sample preparation: Compound 1 was dissolved in methanol to obtain 15 mg / ml; injection: 1.5 ml / needle.

After separation, the fraction was concentrated and dried by a rotary evaporator at 40 ° C to give two optical isomer compounds 2-1 (360 mg), Compound 2-2 (300 mg).

Compound 2-1

1H NMR (400MHz, CDCl ₃ ) δ 8.33 (s, 1H), 8.05 (s, 1H), 7.22 (m, 4H), 7.14 (m, 4H), 7.07 (m, 1H), 7.04-6.96 (m) , 4H), 6.94-6.85 (m, 4H), 6.23 (s, 2H), 5.65 (t, 1H), 4.52 (d, 1H), 4.36 (dd, 1H), 4.16-3.97 (m, 2H), 3.90 (dd, 2H), 3.67 (t, 1H), 3.60 (dd, 1H), 2.99-2.90 (m, 1H), 1.97-1.83 (m, 2H), 1.82-1.69 (m, 2H), 1.24 ( d, 3H), 1.18 (d, 3H).

MS M/Z (ESI): 826.2 (M+1).

³¹ P NMR (CDCl 3 ) δ 22.75.

Compound 2-2

_{1H NMR (400MHz, CDCl 3)} δ8.29 (s, 1H), 8.02 (s, 1H), 7.30-7.22 (m, 3H), 7.19 (m, 4H), 7.10 (m, 4H), 6.97 (t , 2H), 6.87 (dd, 4H), 6.11 (s, 2H), 5.64 (t, 1H), 4.48 (d, 1H), 4.41 (dd, 1H), 4.17-4.03 (m, 2H), 3.95- 3.88 (m, 2H), 3.68-3.56 (m, 2H), 2.98 (m, 1H), 2.02-1.93 (m, 2H), 1.80-1.74 (m, 2H), 1.19 (d, 3H), 1.13 ( d, 3H).

MS M/Z (ESI): 826.2 (M+1).

³¹ P NMR (CDCl 3 ) δ 23.77.

Test case

Test Example 1. Screening for anti-hepatitis B virus activity

Compounds were tested for anti-HBV activity using HepG 2.2.15 cells. The materials and instruments used were as follows: HepG2.2.15 cells, RPMI 1640 medium, fetal bovine serum, 96-well plates, DMSO, QIAamp 96 DNA Blood Kit, Cell-titer blue, microplate reader, Applied Biosystems 7900 real-time PCR system.

Each compound was dissolved in DMSO at 20 mM and stored at -20 ° C, and a 20 mM stock solution of each compound was diluted with a DMSO 3 fold gradient for a total of 9 concentrations. It was further diluted 200-fold with RPMI 1640 medium containing 2.0% FBS. The highest test final concentration of the compound was 100 μM. The experimental procedure refers to the QIAamp 96 DNABlood Kit (QIAGEN51161) instructions.

qPCR Determination of anti-HBV activity of a compound was calculated EC ₅₀ (median effective inhibitory concentration). Analysis of data and calculation of percent inhibition: The percentage of inhibition was calculated using the following formula: inhibition rate (%) = (total amount of HBV in the DMSO control group - total amount of HBV in the test sample group) / total amount of HBV in the DMSO control group × 100. Finally, EC ₅₀ values _were calculated using GraphPad Prism software compound.

The cytotoxicity of the compounds was determined by the Cell-titer blue method and the CC ₅₀ (to 50% cytotoxic concentration) was calculated. Analyze data and calculate relative cell viability: Calculate the percentage of cell viability using the following formula: cell viability (%) = (fluorescence value of the test sample - background fluorescence value) / (fluorescence value of the DMSO control group - background fluorescence value) × 100. Finally, compound CC ₅₀ values _are calculated using GraphPad Prism software. The results are shown in the following table:

Table 1: EC ₅₀ values and CC ₅₀ values for each compound

Serial number	Compound number	EC 50 (nM)	CC 50 (μM)
				1	Compound 2-1	85.95	>11.1
2	Compound 2-2	48.31	>11.1

Conclusion: The test compounds all showed good anti-HBV activity and showed no cytotoxicity within the tested concentration range (0.0152-100 μM).

Test Example 2, Pharmacokinetic Evaluation

Beagle (purchased from Chengdu Dashuo Biotechnology Co., Ltd., license number SCXK (Chuan) 2013-24) 8-12kg, fasted overnight. On the day of the experiment, 3 Beagle dogs were given 2-1 intravenously (2-2 insoluble and could not be administered intravenously), before administration and 5, 15, 30 minutes, 1, 2, 4, 8, 12 and 24 hours after administration. Blood was collected from the forelimb venous blood by 1.0 mL (heparin anticoagulation), and plasma was collected. After one week of elution, 6 Beagle dogs were intragastrically administered with test compounds 2-1 and 2-2, respectively, before administration and given At 5, 15, 30, 1, 2, 4, 8, 12 and 24 h after the drug, 1.0 mL (heparin anticoagulation) was collected from the forelimb venous vein, and plasma was collected. 150 μL of acetonitrile (containing verapamil, 5.0 ng·mL-1 and glibenclamide, 50.0 ng·mL-1) was added to 30 μL of plasma, vortexed for 10 min, and centrifuged at 3700 rpm for 18 min. 70 μL of the supernatant was taken, 70 μL of water was added, and the mixture was vortexed for 10 minutes, and then 10 μL was taken for LC-MS/MS detection. The pharmacokinetic parameters were calculated using a non-compartmental model from Pharsight Phoenix 6.3. The experimental results are shown in Table 2.

Table 2: Results of canine pharmacokinetic evaluation

Conclusion: The experimental results show that the compound 2-1 of the present invention has a higher exposure amount in canine plasma, and a lower exposure amount of PMPA, and therefore the compound 2-1 of the present invention has good plasma stability; in combination with the above test example 1 The test results can predict that the compound of the present invention has a good anti-hepatitis B virus potential, and also has a significant effect of reducing the toxic side effects produced by the metabolism of PMPA in plasma.

Claims (10)

1. A substituted phosphoramidate derivative represented by the formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof, wherein:

   

   A is selected from phenyl or naphthyl, and the phenyl or naphthyl group is further optionally 0 to 5 selected from the group consisting of H, F, Cl, Br, I, amino, hydroxy, carboxy, C _1-4 alkyl or Substituted by a substituent of a C _1-4 alkoxy group;

   B is

   

   E is selected from -CH(CH ₂ F)CH ₂ -, -CH ₂ CH(CH ₃ )OCH ₂ - or -CH ₂ CH ₂ OCH ₂ -;

   R ^{1 is} selected from H or C _1-4 alkyl;

   R ² is a side chain of a natural or pharmaceutically acceptable amino acid, and if the side chain contains a carboxyl group, the carboxyl group may be optionally esterified with an alkyl group or an aryl group;

   R ³ is

   

   R ^{4 is} selected from H, formyl, C _1-4 alkyl, -(CH ₂ ) _n -C _3-6 carbocyclic, -(C=O)-C _1-4 alkyl or -(C=O) -C _3-6 carbon ring;

   n is selected from 0, 1, or 2.
2. The substituted phosphoramidate derivative according to claim 1, which is a stereoisomer or a pharmaceutically acceptable salt, wherein the substituted phosphoramidate derivative is selected from the compounds of the formula (II) ,among them

   

   E is selected from -CH ₂ CH(CH ₃ )OCH ₂ - or -CH ₂ CH ₂ OCH ₂ -;

   R ^{2 is} selected from the side chain of glycine, alanine, leucine, phenylalanine, asparagine or arginine;

   R ^{4 is} selected from H, methyl, phenyl, benzyl, formyl, acetyl or benzoyl.
3. The substituted phosphoramidate derivative according to claim 2, which is a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the substituted phosphoramidate derivative is selected from the compounds of the formula (II) ,among them:

   E is selected from -CH ₂ CH(CH ₃ )OCH ₂ -;

   R ^{2 is} selected from the side chain of glycine, alanine or phenylalanine;

   R ^{4 is} selected from H, benzyl, formyl, acetyl or benzoyl.
4. The substituted phosphoramidate derivative according to claim 3, which is a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the substituted phosphoramidate derivative is selected from the compounds of the formula (III) ,

   
5. The substituted phosphoramidate derivative according to claim 1, which is a stereoisomer or a pharmaceutically acceptable salt, wherein the compound is:

   
6. A pharmaceutical composition comprising a therapeutically effective amount of the substituted phosphoramidate derivative according to any one of claims 1 to 5, and a stereoisomer or pharmaceutically acceptable salt thereof, And a pharmaceutically acceptable carrier or excipient.
7. Use of the substituted phosphoramidate derivative according to any one of claims 1 to 5, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating a viral infectious disease.
8. The use according to claim 7, wherein said viral infectious disease comprises hepatitis B virus, type C Infectious diseases caused by hepatitis virus and HIV virus.
9. A method of treating a viral infectious disease, wherein the method comprises administering a substituted phosphoramidate derivative according to any one of claims 1 to 5, a stereoisomer thereof, or a pharmaceutically acceptable thereof Salt or the pharmaceutical composition of claim 6.
10. The method according to claim 9, wherein the viral infectious disease comprises an infectious disease caused by hepatitis B virus, hepatitis C virus, and HIV virus.